Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to the C-terminal residues 111-131 of human alpha-Synuclein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4, with 1% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-21121 detects apha Synuclein in human and rat samples.
PA1-21121 has been successfully used in immunohistochemistry (FFPE) procedures. No special pretreatment is required for formalin-fixed paraffin-embedded tissue sections.
The PA1-21121 immunogen is a synthetic peptide corresponding to the C-terminal residues 111-131 of human alpha Synuclein.
The implication of alpha synuclein in neurodegenerative diseases started after the identification of non A beta component of amyloid (NAC peptide) in Alzheimer's disease (AD) brains. There is now a general group of synucleinopathies which implicates alpha synuclein in Lewy body syndromes, Parkinson' disease, and Alzheimer's disease. Certain missense mutations in the alpha synuclein gene (A53T, A30P) have been linked to the familial Parkinson's disease (PD). Alpha Synuclein is the major component of Lewy bodies and Lewy neuritis in sporadic PD, dementia with Lewy Bodies and Lewy Body variant of AD.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
alpha-synuclein; NACP; non A-beta component of AD amyloid; synuclein alpha-140; synuclein, alpha (non A4 component of amyloid precursor)
NACP; PARK1; PARK4; PD1; SNCA